Goal 3: Advance Translational Research

Novel Mechanism for Clinical Trials of New Pro-Hemostatic Agents in Hemophilia

There are new exciting novel pro-hemostatic therapeutics in early phase clinical trials for hemophilia and hemophilia inhibitor patients. Yet, it is difficult to design randomized trials to compare these agents, or compare them with standard treatment, given the small sample size and competing studies for such patients. It is critical to develop novel approaches to compare new agents in rare populations. For example, sequential design might study three drugs, but start with 2 drugs in a small number of patients, and comparing the superor drug to a third drug, requiring smaller sample size.

Tags (Keywords associated with the idea)


6 net votes
15 up votes
9 down votes
Idea No. 605